A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
A four-arm community trial finds integrated diabetes-and-periodontitis self-management improves glycaemic control and oral health more than single-disease care. PICO summary and commentary.
A controlled study finds adding vildagliptin to premixed insulin reduces glycaemic variability and improves time in range in type 2 diabetes. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…
Summary: In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of…
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.